{"id":50805,"date":"2022-11-14T14:02:05","date_gmt":"2022-11-14T13:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/orionis-biosciences-presents-preclinical-data-on-interferon-and-il-2-targeted-cytokine-immunotherapies-for-cancer\/"},"modified":"2022-11-14T14:02:05","modified_gmt":"2022-11-14T13:02:05","slug":"orionis-biosciences-presents-preclinical-data-on-interferon-and-il-2-targeted-cytokine-immunotherapies-for-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/orionis-biosciences-presents-preclinical-data-on-interferon-and-il-2-targeted-cytokine-immunotherapies-for-cancer\/","title":{"rendered":"Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer"},"content":{"rendered":"
\n

\nCompany shared progress from its proprietary A-Kine\u2122 platform for engineering of target-selective, cis-acting cytokine immunotherapies at 2022 PEGS Europe Protein and Antibody Engineering Summit<\/i>\n<\/p>\n

\nData demonstrate potent single-agent anti-tumor activity of immune cell-targeted interferons and interleukin-2 through remodeling of tumor microenvironments and cancer immunity cycle in syngeneic and humanized mouse models<\/i>\n<\/p>\n

\nOrionis anticipates IND submission and start of conditionally active cytokine Phase 1 trial in 2023<\/i>\n<\/p>\n

BOSTON & GHENT, Belgium–(BUSINESS WIRE)–Orionis Biosciences<\/a>, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine\u2122 platform for rational design of cis-acting immuno-cytokines at the 14th<\/sup> Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 \u2013 16 in Barcelona, Spain. The data demonstrate potent anti-tumor activity across multiple classes of targeted cytokines.\n<\/p>\n

<\/a><\/p>\n

\nCytokines are powerful regulators of the immune system and attractive therapeutic effector candidates. However, their sites of action must be restricted to avoid systemic toxicity. To achieve spatial control of cytokine bioactivity, Orionis has developed a proprietary biologics platform that integrates a strategic \u201cplug-and-play\u201d assembly of modular biomolecular building blocks into therapeutic agents with unique conditional effector functions and cell-target selectivity. These conditionally active, cis-acting cytokines aim to trigger anti-tumor immune responses even in cold tumors that lack prevalent immune involvement and are refractory to checkpoint inhibitor and other therapies.\n<\/p>\n

\n\u201cToday we shared preclinical data that represent exciting progress for our proprietary A-Kine platform. Our R&D engine, inspired by nature\u2019s intrinsic mechanisms for disease control, has the potential to address some of the biggest challenges in oncology drug discovery and beyond,\u201d said Nikolai Kley, Ph.D., Founder, President and Chief Executive Officer of Orionis Biosciences. \u201cAs we look ahead, we anticipate IND submission and the start of a conditionally active cytokine Phase 1 trial in 2023.\u201d\n<\/p>\n

\nOrionis\u2019 deep and diversified A-Kine pipeline comprises multiple cytokine classes, including re-engineered interferons (IFNs), interleukins (ILs) and tumor necrosis factors (TNFs). In conjunction with an arsenal of cell-targeting strategies, Orionis is harnessing the therapeutic potential of these cytokines to reprogram immune cells and reactivate the cancer immunity cycle, and thereby the immune system\u2019s natural mechanisms of disease control.\n<\/p>\n

\nThe company presented its advances and breakthroughs in design, engineering and development of exquisitely target-selective A-Kines incorporating:\n<\/p>\n